IL163745A0 - Use of adenoviruses mutated in the va genes for cancer treatment - Google Patents
Use of adenoviruses mutated in the va genes for cancer treatmentInfo
- Publication number
- IL163745A0 IL163745A0 IL16374503A IL16374503A IL163745A0 IL 163745 A0 IL163745 A0 IL 163745A0 IL 16374503 A IL16374503 A IL 16374503A IL 16374503 A IL16374503 A IL 16374503A IL 163745 A0 IL163745 A0 IL 163745A0
- Authority
- IL
- Israel
- Prior art keywords
- cancer treatment
- genes
- adenovirus
- adenoviruses
- mutated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10364—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200200716 | 2002-03-26 | ||
PCT/ES2003/000140 WO2003080083A1 (es) | 2002-03-26 | 2003-03-25 | Uso de adenovirus mutados en los genes va para el tratamiento del cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163745A0 true IL163745A0 (en) | 2005-12-18 |
Family
ID=27772025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16374503A IL163745A0 (en) | 2002-03-26 | 2003-03-25 | Use of adenoviruses mutated in the va genes for cancer treatment |
IL163745A IL163745A (en) | 2002-03-26 | 2004-08-26 | Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL163745A IL163745A (en) | 2002-03-26 | 2004-08-26 | Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment |
Country Status (14)
Country | Link |
---|---|
US (3) | US7344711B2 (xx) |
EP (2) | EP1605053A1 (xx) |
JP (2) | JP2005526099A (xx) |
AT (1) | ATE309812T1 (xx) |
AU (1) | AU2003226835B2 (xx) |
BR (1) | BR0308634A (xx) |
CA (1) | CA2478616C (xx) |
DE (1) | DE60302350T2 (xx) |
DK (1) | DK1498129T3 (xx) |
ES (1) | ES2248764T3 (xx) |
HK (1) | HK1071060A1 (xx) |
IL (2) | IL163745A0 (xx) |
MX (1) | MXPA04009204A (xx) |
WO (1) | WO2003080083A1 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7344711B2 (en) * | 2002-03-26 | 2008-03-18 | Oncolytics Biotech Inc. | Use of adenoviruses mutated in the VA genes for cancer treatment |
US10260049B2 (en) | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
WO2007103825A2 (en) * | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
ES2355882B1 (es) | 2009-03-24 | 2012-02-13 | INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) | Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer. |
JPWO2012121071A1 (ja) * | 2011-03-04 | 2014-07-17 | 国立大学法人大阪大学 | VA−RNAsが発現しないアデノウイルスベクター |
JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
CA3149478A1 (en) | 2019-08-05 | 2021-02-11 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
US20230293590A1 (en) | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5079159A (en) * | 1983-12-27 | 1992-01-07 | Genetics Institute, Inc. | Method for making tissue plasminogen activator |
JP2648301B2 (ja) * | 1983-12-27 | 1997-08-27 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | 真核細胞の形質転換のための補助dnaを含むベクター |
US5002874A (en) * | 1987-09-17 | 1991-03-26 | Genetics Institute, Inc. | Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α |
US5985846A (en) * | 1995-06-07 | 1999-11-16 | Baylor College Of Medicine | Gene therapy for muscular dystrophy |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
US5981225A (en) * | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
WO1999057296A1 (en) * | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
MXPA02004736A (es) * | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
WO2003022311A1 (en) * | 2001-09-13 | 2003-03-20 | Genvec, Inc. | Adenoviral vector and related system and methods of making and use |
US7344711B2 (en) * | 2002-03-26 | 2008-03-18 | Oncolytics Biotech Inc. | Use of adenoviruses mutated in the VA genes for cancer treatment |
CA2507036A1 (en) * | 2002-12-02 | 2004-06-17 | Genvec, Inc. | Materials and methods for treating ocular-related disorders |
-
2003
- 2003-03-25 US US10/509,194 patent/US7344711B2/en not_active Expired - Lifetime
- 2003-03-25 JP JP2003577909A patent/JP2005526099A/ja active Pending
- 2003-03-25 ES ES03744873T patent/ES2248764T3/es not_active Expired - Lifetime
- 2003-03-25 DK DK03744873T patent/DK1498129T3/da active
- 2003-03-25 CA CA2478616A patent/CA2478616C/en not_active Expired - Fee Related
- 2003-03-25 DE DE60302350T patent/DE60302350T2/de not_active Expired - Lifetime
- 2003-03-25 AT AT03744873T patent/ATE309812T1/de not_active IP Right Cessation
- 2003-03-25 EP EP05016560A patent/EP1605053A1/en not_active Withdrawn
- 2003-03-25 MX MXPA04009204A patent/MXPA04009204A/es active IP Right Grant
- 2003-03-25 EP EP03744873A patent/EP1498129B1/en not_active Expired - Lifetime
- 2003-03-25 WO PCT/ES2003/000140 patent/WO2003080083A1/es active IP Right Grant
- 2003-03-25 IL IL16374503A patent/IL163745A0/xx unknown
- 2003-03-25 BR BR0308634-8A patent/BR0308634A/pt not_active IP Right Cessation
- 2003-03-25 AU AU2003226835A patent/AU2003226835B2/en not_active Ceased
-
2004
- 2004-08-26 IL IL163745A patent/IL163745A/en not_active IP Right Cessation
-
2005
- 2005-04-04 HK HK05102827A patent/HK1071060A1/xx not_active IP Right Cessation
-
2007
- 2007-05-31 US US11/809,191 patent/US20090202489A2/en not_active Abandoned
-
2010
- 2010-05-27 US US12/789,270 patent/US20110053249A1/en not_active Abandoned
- 2010-06-01 JP JP2010126305A patent/JP2010184940A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20110053249A1 (en) | 2011-03-03 |
AU2003226835B2 (en) | 2006-11-09 |
DE60302350D1 (de) | 2005-12-22 |
DE60302350T2 (de) | 2006-08-03 |
BR0308634A (pt) | 2005-02-15 |
EP1605053A1 (en) | 2005-12-14 |
JP2005526099A (ja) | 2005-09-02 |
CA2478616A1 (en) | 2003-10-02 |
AU2003226835A1 (en) | 2003-10-08 |
DK1498129T3 (da) | 2006-04-03 |
US20090202489A2 (en) | 2009-08-13 |
CA2478616C (en) | 2012-05-29 |
US7344711B2 (en) | 2008-03-18 |
US20060233753A1 (en) | 2006-10-19 |
WO2003080083A1 (es) | 2003-10-02 |
HK1071060A1 (en) | 2005-07-08 |
EP1498129B1 (en) | 2005-11-16 |
MXPA04009204A (es) | 2004-11-26 |
US20080089864A1 (en) | 2008-04-17 |
ATE309812T1 (de) | 2005-12-15 |
EP1498129A1 (en) | 2005-01-19 |
JP2010184940A (ja) | 2010-08-26 |
ES2248764T3 (es) | 2006-03-16 |
IL163745A (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071060A1 (en) | Use of adenoviruses mutated in the va genes for cancer treatment | |
WO2004066941A3 (en) | Expression profiles for colon cancer and methods of use | |
HK1123313A1 (en) | Methods and compositions for gene inactivation | |
AU2002360820A1 (en) | Compositions for dna mediated gene silencing | |
EP2639319A3 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
WO2008005562A3 (en) | Rna silencing compositions and methods for the treatment of huntington's disease | |
WO2001077164A8 (en) | Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis | |
PL1730315T3 (pl) | Polimorfizmy w genie NOD2/CARD15 | |
WO2005032495A3 (en) | Gene expression profiles and methods of use | |
WO2005010149A3 (en) | Subgroup b adenoviral vectors for treating disease | |
AU2002359645A1 (en) | Targeted genetic risk-stratification using microarrays | |
MXPA05008329A (es) | Uso de un polimorfismo novedoso en el gen hsgk1 para el diagnostico de hipertonia y el uso de la familia del gen sgk en el diagnostico y terapia del sindrome q/t largo. | |
WO2003000896A3 (en) | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE | |
WO2001040521A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
MXPA05005120A (es) | Secuencias de adn de la region genomica tcd de photorhabdus luminescens. | |
WO2002101048A3 (en) | NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE | |
AU2001287631A1 (en) | Nucleotide sequences which code for the metf gene | |
AU2002212232A1 (en) | Nucleotide sequences which code for the dps gene | |
AU2001278509A1 (en) | Nucleotide sequences which code for the atr43 gene | |
WO2006133866A3 (en) | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients | |
AU2001282084A1 (en) | Nucleotide sequences which code for the sigh gene | |
WO2002083733A3 (en) | Polynucleotides and polypeptides of the ifnalpha-6 gene | |
WO2002089829A3 (en) | Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer | |
AU7666900A (en) | Nucleotide sequences derived from genes coding for trimethylamine n-oxide reductase, uses thereof in particular for detecting bacteria | |
AU2001295470A1 (en) | Nucleotide sequences which code for the gpmb gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of name of proprietor(s) |